[Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].

Abstract

The clinical efficacy of vectrine (erdosteine) was evaluated in the treatment of chronic bronchitis patients with hypersecretion during a controlled clinical trial having included 170 patients. For inclusion, the bronchitis patients had to be in a stable status (no exacerbation since at least three months). The patients received, in double-blind protocol, vectrine, one capsule b.i.d. or placebo, one similar capsule b.i.d. during a period treatment of 21 days. The results of the main evaluation criteria, the global index of efficacy (frequency of the cough + severity of the cough + difficulty in breathing + dyspnea) but also on the intensity and frequency of the cough were statistically significant in favor of vectrine. The safety of the treatment was excellent.

• Authors: M Aubier, L Berdah
• Journal: Revue des maladies respiratoires (Rev Mal Respir) Vol. 16 Issue 4 Pg. 521-8 (Sep 1999) ISSN: 0761-8425 [Print] France
• Vernacular Title: Etude multicentrique, controlée, en double aveugle, de l'efficacité et de la tolérance de Vectrine (erdostéine) versus placebo dans le traitement de la bronchite chronique hypersecrétante stabilisée.
• PMID: 10549062 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Expectorants
• Thioglycolates
• Thiophenes
• erdosteine

Topics

• Administration, Oral
• Adult
• Aged
• Bronchitis (drug therapy, pathology)
• Chronic Disease
• Double-Blind Method
• Dyspnea
• Expectorants (administration & dosage, pharmacology, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Severity of Illness Index
• Thioglycolates (adverse effects, pharmacology, therapeutic use)
• Thiophenes (adverse effects, pharmacology, therapeutic use)
• Treatment Outcome